Selected research
Industry Research
Remicade Biosimilar Industry Research Report 2026
Market perspective
The global Remicade Biosimilar market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Remicade Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Remicade Biosimilar is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Remicade Biosimilar is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Remicade Biosimilar include Walvax Biotechnology, Livzon Pharmaceutical, Hualan Biological Engineering, Hisun Pharmaceutical, Fosun Pharmaceutical, Anke Biotechnology, Synthon Pharmaceuticals, Novartis (Sandoz) and Merck Serono (Merck Group), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Remicade Biosimilar market in terms of revenue (US$ million) and, where applicable, sales volume (L), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/L) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Remicade Biosimilar Market by Company
Walvax Biotechnology
Livzon Pharmaceutical
Hualan Biological Engineering
Hisun Pharmaceutical
Fosun Pharmaceutical
Anke Biotechnology
Synthon Pharmaceuticals
Novartis (Sandoz)
Merck Serono (Merck Group)
LG Life Sciences
Hospira
Genentech (Roche Group)
Celltrion
Biogen idec Inc.
Biocon
Remicade Biosimilar Segment by Type
100mg/10ml
500mg/50ml
Remicade Biosimilar Segment by Application
Blood Disorders
Oncology Diseases
Remicade Biosimilar Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Remicade Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Remicade Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Remicade Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Remicade Biosimilar manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Remicade Biosimilar by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Remicade Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 100mg/10ml
- 500mg/50ml
Applications
- Blood Disorders
- Oncology Diseases
Companies covered
- Walvax Biotechnology
- Livzon Pharmaceutical
- Hualan Biological Engineering
- Hisun Pharmaceutical
- Fosun Pharmaceutical
- Anke Biotechnology
- Synthon Pharmaceuticals
- Novartis (Sandoz)
- Merck Serono (Merck Group)
- LG Life Sciences
- Hospira
- Genentech (Roche Group)
- Celltrion
- Biogen idec Inc.
- Biocon
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Remicade Biosimilar Market Size (2021-2032)
- 2.2.2 Global Remicade Biosimilar Sales (2021-2032)
- 2.2.3 Global Remicade Biosimilar Market Average Price (2021-2032)
- 2.3 Remicade Biosimilar by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 100mg/10ml
- 2.3.3 500mg/50ml
- 2.4 Remicade Biosimilar by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Blood Disorders
- 2.4.3 Oncology Diseases
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Remicade Biosimilar Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Remicade Biosimilar Sales (L) of Manufacturers (2021-2026)
- 3.3 Global Remicade Biosimilar Revenue of Manufacturers (2021-2026)
- 3.4 Global Remicade Biosimilar Average Price by Manufacturers (2021-2026)
- 3.5 Global Remicade Biosimilar Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Remicade Biosimilar, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Remicade Biosimilar, Product Type & Application
- 3.8 Global Manufacturers of Remicade Biosimilar, Established Date
- 3.9 Global Remicade Biosimilar Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Walvax Biotechnology
- 4.1.1 Walvax Biotechnology Company Information
- 4.1.2 Walvax Biotechnology Business Overview
- 4.1.3 Walvax Biotechnology Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Walvax Biotechnology Remicade Biosimilar Product Portfolio
- 4.1.5 Walvax Biotechnology Recent Developments
- 4.2 Livzon Pharmaceutical
- 4.2.1 Livzon Pharmaceutical Company Information
- 4.2.2 Livzon Pharmaceutical Business Overview
- 4.2.3 Livzon Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Livzon Pharmaceutical Remicade Biosimilar Product Portfolio
- 4.2.5 Livzon Pharmaceutical Recent Developments
- 4.3 Hualan Biological Engineering
- 4.3.1 Hualan Biological Engineering Company Information
- 4.3.2 Hualan Biological Engineering Business Overview
- 4.3.3 Hualan Biological Engineering Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hualan Biological Engineering Remicade Biosimilar Product Portfolio
- 4.3.5 Hualan Biological Engineering Recent Developments
- 4.4 Hisun Pharmaceutical
- 4.4.1 Hisun Pharmaceutical Company Information
- 4.4.2 Hisun Pharmaceutical Business Overview
- 4.4.3 Hisun Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hisun Pharmaceutical Remicade Biosimilar Product Portfolio
- 4.4.5 Hisun Pharmaceutical Recent Developments
- 4.5 Fosun Pharmaceutical
- 4.5.1 Fosun Pharmaceutical Company Information
- 4.5.2 Fosun Pharmaceutical Business Overview
- 4.5.3 Fosun Pharmaceutical Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Fosun Pharmaceutical Remicade Biosimilar Product Portfolio
- 4.5.5 Fosun Pharmaceutical Recent Developments
- 4.6 Anke Biotechnology
- 4.6.1 Anke Biotechnology Company Information
- 4.6.2 Anke Biotechnology Business Overview
- 4.6.3 Anke Biotechnology Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Anke Biotechnology Remicade Biosimilar Product Portfolio
- 4.6.5 Anke Biotechnology Recent Developments
- 4.7 Synthon Pharmaceuticals
- 4.7.1 Synthon Pharmaceuticals Company Information
- 4.7.2 Synthon Pharmaceuticals Business Overview
- 4.7.3 Synthon Pharmaceuticals Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Synthon Pharmaceuticals Remicade Biosimilar Product Portfolio
- 4.7.5 Synthon Pharmaceuticals Recent Developments
- 4.8 Novartis (Sandoz)
- 4.8.1 Novartis (Sandoz) Company Information
- 4.8.2 Novartis (Sandoz) Business Overview
- 4.8.3 Novartis (Sandoz) Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novartis (Sandoz) Remicade Biosimilar Product Portfolio
- 4.8.5 Novartis (Sandoz) Recent Developments
- 4.9 Merck Serono (Merck Group)
- 4.9.1 Merck Serono (Merck Group) Company Information
- 4.9.2 Merck Serono (Merck Group) Business Overview
- 4.9.3 Merck Serono (Merck Group) Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Merck Serono (Merck Group) Remicade Biosimilar Product Portfolio
- 4.9.5 Merck Serono (Merck Group) Recent Developments
- 4.10 LG Life Sciences
- 4.10.1 LG Life Sciences Company Information
- 4.10.2 LG Life Sciences Business Overview
- 4.10.3 LG Life Sciences Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 LG Life Sciences Remicade Biosimilar Product Portfolio
- 4.10.5 LG Life Sciences Recent Developments
- 4.11 Hospira
- 4.11.1 Hospira Company Information
- 4.11.2 Hospira Business Overview
- 4.11.3 Hospira Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Hospira Remicade Biosimilar Product Portfolio
- 4.11.5 Hospira Recent Developments
- 4.12 Genentech (Roche Group)
- 4.12.1 Genentech (Roche Group) Company Information
- 4.12.2 Genentech (Roche Group) Business Overview
- 4.12.3 Genentech (Roche Group) Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Genentech (Roche Group) Remicade Biosimilar Product Portfolio
- 4.12.5 Genentech (Roche Group) Recent Developments
- 4.13 Celltrion
- 4.13.1 Celltrion Company Information
- 4.13.2 Celltrion Business Overview
- 4.13.3 Celltrion Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Celltrion Remicade Biosimilar Product Portfolio
- 4.13.5 Celltrion Recent Developments
- 4.14 Biogen idec Inc.
- 4.14.1 Biogen idec Inc. Company Information
- 4.14.2 Biogen idec Inc. Business Overview
- 4.14.3 Biogen idec Inc. Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Biogen idec Inc. Remicade Biosimilar Product Portfolio
- 4.14.5 Biogen idec Inc. Recent Developments
- 4.15 Biocon
- 4.15.1 Biocon Company Information
- 4.15.2 Biocon Business Overview
- 4.15.3 Biocon Remicade Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Biocon Remicade Biosimilar Product Portfolio
- 4.15.5 Biocon Recent Developments
5 Global Remicade Biosimilar Market Scenario by Region
- 5.1 Global Remicade Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Remicade Biosimilar Sales by Region: 2021-2032
- 5.2.1 Global Remicade Biosimilar Sales by Region: 2021-2026
- 5.2.2 Global Remicade Biosimilar Sales by Region: 2027-2032
- 5.3 Global Remicade Biosimilar Revenue by Region: 2021-2032
- 5.3.1 Global Remicade Biosimilar Revenue by Region: 2021-2026
- 5.3.2 Global Remicade Biosimilar Revenue by Region: 2027-2032
- 5.4 North America Remicade Biosimilar Market Facts & Figures by Country
- 5.4.1 North America Remicade Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Remicade Biosimilar Sales by Country (2021-2032)
- 5.4.3 North America Remicade Biosimilar Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Remicade Biosimilar Market Facts & Figures by Country
- 5.5.1 Europe Remicade Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Remicade Biosimilar Sales by Country (2021-2032)
- 5.5.3 Europe Remicade Biosimilar Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Remicade Biosimilar Market Facts & Figures by Country
- 5.6.1 Asia Pacific Remicade Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Remicade Biosimilar Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Remicade Biosimilar Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Remicade Biosimilar Market Facts & Figures by Country
- 5.7.1 South America Remicade Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Remicade Biosimilar Sales by Country (2021-2032)
- 5.7.3 South America Remicade Biosimilar Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Remicade Biosimilar Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Remicade Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Remicade Biosimilar Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Remicade Biosimilar Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Remicade Biosimilar Sales by Type (2021-2032)
- 6.1.1 Global Remicade Biosimilar Sales by Type (2021-2032) & (L)
- 6.1.2 Global Remicade Biosimilar Sales Market Share by Type (2021-2032)
- 6.2 Global Remicade Biosimilar Revenue by Type (2021-2032)
- 6.2.1 Global Remicade Biosimilar Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Remicade Biosimilar Revenue Market Share by Type (2021-2032)
- 6.3 Global Remicade Biosimilar Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Remicade Biosimilar Sales by Application (2021-2032)
- 7.1.1 Global Remicade Biosimilar Sales by Application (2021-2032) & (L)
- 7.1.2 Global Remicade Biosimilar Sales Market Share by Application (2021-2032)
- 7.2 Global Remicade Biosimilar Revenue by Application (2021-2032)
- 7.2.1 Global Remicade Biosimilar Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Remicade Biosimilar Revenue Market Share by Application (2021-2032)
- 7.3 Global Remicade Biosimilar Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Remicade Biosimilar Value Chain Analysis
- 8.1.1 Remicade Biosimilar Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Remicade Biosimilar Production Mode & Process
- 8.2 Remicade Biosimilar Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Remicade Biosimilar Distributors
- 8.2.3 Remicade Biosimilar Customers
9 Global Remicade Biosimilar Analyzing Market Dynamics
- 9.1 Remicade Biosimilar Industry Trends
- 9.2 Remicade Biosimilar Industry Drivers
- 9.3 Remicade Biosimilar Industry Opportunities and Challenges
- 9.4 Remicade Biosimilar Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst